Scientific Reports 6: Article number: 35050 10.1038/srep35050; published online: October 12 2016; updated: December 19 2016
This Article contains errors in Table 2, where the ‘Sensitivity’ and ‘Youden Index’ values for AFP + PIVKA-II (≥5.0 or ≥32.0) are incorrectly given as 27.8% and 3.7% respectively. The correct Table 2 appears below.
Table 2. Sensitivity and Specificity of PIVKA-II and AFP in differentiating HCC cases from controls at two fixed cut-off values.
| Months before HCC diagnosis | Sensitivity | Specificity | Youden Index | Sensitivity | Specificity | Youden Index |
|---|---|---|---|---|---|---|
| PIVKA-II (mAU/ml) | ≥32.0 | ≥100 | ||||
| −12 | 31.4% | 93.5% | 24.9% | 2.9% | 100% | 2.9% |
| −9 | 27.8% | 94.4% | 22.2% | 5.6% | 99.1% | 4.7% |
| −6 | 38.9% | 92.6% | 31.5% | 8.3% | 100% | 8.3% |
| −3 | 41.7% | 92.6% | 34.3% | 19.4% | 100% | 19.4% |
| 0 | 58.3% | 92.6% | 50.9% | 36.1% | 100% | 36.1% |
| AFP (ng/ml) | ≥5.0 | ≥200 | ||||
| −12 | 51.4% | 77.8% | 29.2% | 2.9% | 100% | 2.9% |
| −9 | 47.2% | 77.8% | 25.0% | 0 | 100% | 0 |
| −6 | 55.6% | 88.0% | 43.6% | 5.6% | 100% | 5.6% |
| −3 | 66.7% | 88.9% | 55.6% | 16.7% | 100% | 16.7% |
| 0 | 75.0% | 91.7% | 66.7% | 19.4% | 100% | 19.4% |
| AFP +PIVKA-II | ≥5.0 or ≥32.0 | ≥5.0 and ≥32.0 | ||||
| −12 | 77.2% | 75.9% | 53.1% | 13.8% | 98.1% | 11.9% |
| −9 | 61.1% | 75.0% | 36.1% | 13.8% | 98.1% | 11.9% |
| −6 | 72.2% | 82.4% | 54.6% | 22.2% | 99.1% | 21.3% |
| −3 | 77.8% | 82.4% | 60.2% | 16.7% | 100% | 16.7% |
| 0 | 88.9% | 85.2% | 74.1% | 25.0% | 100% | 25.0% |
PIVKA-II: Protein Induced by Vitamin K Absence or Antagonist-II; AFP: α-fetoprotein; HCC: hepatocellular carcinoma.
*or: Positive is defined as either PIVKA-II or AFP above cut-off value.
**and: Positive is defined as both PIVKA-II and AFP above cut-off value.